Results released from SUSTAIN 6 trial16 Sep 2016
Results have just been released from the SUSTAIN 6 Trial, funded by Novo Nordisk, which evaluated cardiovascular and other long-term outcomes with semaglutide (a GLP-1 analogue with an extended half-life of approximately 1 week which permits once-weekly subcutaneous administration). The results show that in patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo. The results are published in the New England Journal of Medicine
Professor Steve Bain is the UK Chief Investigator for SUSTAIN 6 and is the Director of the Diabetes Research Unit Cymru funded by Health and Care Research Wales and based in Swansea University Medical School and Assistant Medical Director for Research & Development for ABM University Health Board.